Multiplexed assays for identification of biomarkers and surrogate markers in systemic lupus erythematosus.
Validated biomarkers and surrogate markers are badly needed for monitoring patients with systemic lupus erythematosus (SLE), both for routine clinical care and for clinical trials research. SLE is difficult to study in clinical trials, in part because the disease is so heterogeneous. Very few useful markers have been identified, and even those that historically have been thought to be valid have been recently questioned. This report will focus on the use of emerging multiplexed assay formats that enable analysis of hundreds or even thousands of analytes simultaneously. Their potential and pitfalls for monitoring patients with SLE, particularly those enrolled in clinical trials testing novel therapeutics, will be discussed.
Utz
P J
PJ
Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. pjutz@stanford.edu
D001323:Autoantibodies / Q000097:blood; D015415:Biomarkers / Q000097:blood*; D016207:Cytokines / Q000235:genetics; D020869:Gene Expression Profiling; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000276:immunology; D014158:Transcription, Genetic
D001323:Autoantibodies; D015415:Biomarkers; D016207:Cytokines